Peripheral venous (plasma) insulin and C-peptide concentrations were measured in eight normal subjects given oral or intravenous glucose sufficient to produce similar plasma glucose concentrations. The expected increased insulin response to oral as compared with intravenous glucose was not matched by a comparable increase in C-peptide concentration. The ratio of insulin to C-peptide concentrations doubled 30 minutes after oral glucose was given; no comparable rise was seen with intravenous glucose (p=0-01).
Introduction
Peripheral insulin concentrations are greater after an oral or jejunal glucose load than after an intravenous load.1 It was postulated that gastrointestinal factors that stimulated the release of insulin were released during glucose absorption. Recently several gastrointestinal hormones have been studied to determine whether they fulfil the criteria3 for a hormone responsible for part or all of the enteroinsular axis.4 It is also possible that the nervous system may play a part in the enhanced insulin response to oral glucose.
An investigation5 of the C-peptide secretory response to oral as compared with intravenous glucose in diabetics with heterotopic pancreatic grafts showed no difference between the responses. One report of the insulin and C-peptide responses to oral and intravenous glucose in normal subjects6 suggested that the C-peptide response to oral as opposed to intravenous glucose was not as augmented as that of insulin. As this finding appeared to have been neglected and no confirmatory data or further studies had been published we reinvestigated the problem. The explicit assumption underlying these studies is that insulin and C-peptide are released in equimolar amounts.7
Subjects and methods
We studied eight normal male volunteers (mean ± SD age 26-5 ±3-8 years, mean weight 740±93 kg, mean percentage of ideal body weight 99 8+8-8%). After an overnight fast an intravenous cannula was inserted (into one arm for the study of oral glucose; into both arms for the study of intravenous glucose). The subject remained supine throughout the test and did not smoke, eat, or drink. Studies of oral and intravenous glucose were performed within, or usually at, an interval of one week. In the study of oral glucose 50 g glucose as Lucozade was given at time 0. During the intravenous study infusion of 50% dextrose (Phoenix Pharmaceutical, Gloucester) was begun at time 0. The rate of infusion was adjusted so that concentrations of glucose during this test were similar to those achieved during the study of oral glucose.
Blood was taken at -15, 0, 5, 15, 30, 90, 120, 150, and 180 minutes for estimation of plasma glucose, insulin, and C-peptide concentrations. Glucose concentration was measured by the glucose oxidase method and insulin8 and C-peptide9 concentrations by radioimmunoassay. The interassay variation for insulin was 10-4% and intraassay variation 4 9%. For C-peptide the variations were 12-7% and 3-8% respectively. The sensitivity of the insulin assay was 0-025 nmol/l (15 ng/100 ml) and of the C-peptide assay 0 01 nmol/l (3 ng/100 ml). Informed consent was given by the volunteers after the study had been approved by the hospital ethical committee. The Wilcoxon matched pairs signed rank test was used for all statistical analyses.
Results
Glucose-Plasma concentrations of glucose ( fig 1) Conversion: SI to traditional units-Glucosc 100 ml. Insulin: 1 nmolJl 0 6j&g/100 ml. C 0-3 pgIlO0 ml. The ratio of insulin to C-peptide concentrations in molar terms is shown in fig 2. In the basal state the concentration of C-peptide was about 10 times that of insulin, reflecting the prolonged half life of C-peptide. In contrast to during the intravenous test, when the ratio tended to fall slightly, after oral glucose the ratio rose sharply, reaching significance at 30 minutes (p = 0-O1), by which time it had doubled. It then fell gradually to a value similar to that in the basal state and to that observed after intravenous glucose.
Discussion
This study shows a clear difference in the responses of Cpeptide and insulin, as measured by peripheral plasma concentrations, when stimulated by oral and intravenous glucose in normal subjects. The Rifampicin is an inducer of hepatic drug metabolising enzymes. This results in interactions with several drugs including oral anticoagulants, hypoglycaemics, and contraceptives. Concurrent treatment with prednisolone and rifampicin is given when tuberculosis coexists with a disease that is sensitive to steroids, when the diagnosis is uncertain, or occasionally in the treatment of severe tuberculosis. Two patients with respiratory disease were treated with both drugs: their condition improved considerably after rifampicin was withdrawn. Seven patients were then studied to assess the effect of rifampicin on the pharmacokinetics of prednisolone. Overall, rifampicin increased the plasma clearance of prednisolone by 45% and reduced the amount of drug available to the tissues (area under the plasma concentration time curve) by 66%.
The effectiveness of prednisolone may be considerably reduced when rifampicin and predm'solone are used in combination.
Introduction
Rifampicin is an inducer of the hepatic mixed function oxygenase enzymes involved in drug metabolism. ' 2 Needle biopsy specimens of the liver from patients receiving rifampicin show an increase in cytochrome P4503 and proliferation of smooth endoplasmic reticulum in the hepatocytes.4 Rifampicin induces its own metabolism' during continuous treatment as demonstrated by a shortened half life. In addition, rifampicin can accelerate the elimination of the contraceptive pill,6 leading to menstrual disturbance and unwanted pregnancy. Tolbutamide, hexobarbitone,7 and oral anticoagulants8 are other drugs whose metabolism is similarly affected. Deterioration in renal9 and allograft function'0 associated with concomitant rifampicin treatment may be cited as indirect evidence of the effect of this drug on steroid metabolism.
We report on two patients with respiratory disease in whom rifampicin affected metabolism of steroids; and we describe a study of the effects of rifampicin on the pharmacokinetics of prednisolone in seven patients.
Case reports CASE 1 A 16 year old boy presented with a year's history of symmetrical polyarthropathy, early morning stiffness, and lassitude. Finger clubbing and a rheumatoid nodule at the elbow were noted, and investigation showed a high erythrocyte sedimentation rate and the presence of rheumatoid factor. Rheumatoid arthritis was diagnosed.
A chest x-ray film showed bilateral hilar lymphadenopathy and midzone reticular shadowing. As the most likely diagnosis was thought to be tuberculosis treatment with rifampicin and isoniazid was started. He developed pyrexia, which was ascribed to a possible hypersensitivity reaction to one of these drugs. In an attempt to limit the suspected reaction and because of uncertainty about the diagnosis he was treated additionally with prednisolone 30 mg daily for six weeks. The chest radiographic appearance and symptoms had not improved at the end of this time. Steroid dose was reduced gradually to 10 mg a day but continued at between 7-5 and 15 mg daily concomitantly with
